Novo Nordisk A/S (FRA:NOVA)

Market Cap	187.00B
Revenue (ttm)	40.64B
Net Income (ttm)	14.02B
Shares Out	n/a
EPS (ttm)	3.15
PE Ratio	13.33
Forward PE	12.15
Dividend	1.09 (2.65%)
Ex-Dividend Date	Mar 31, 2025

Volume	23,402
Average Volume	12,890
Open	41.25
Previous Close	41.00
Day's Range	40.00 - 41.25
52-Week Range	40.00 - 126.00
Beta	n/a
RSI	20.38
Earnings Date	Aug 6, 2025

About Aspen Technology

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOVA

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.